This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

Maternal Immunisation
Maternal
ImmunisationMaternal Immunisation HomepageSafety ProfileDosing
Adults
AdultsAdults HomepageSafety ProfileDosing
Preparation
Private Market
Useful Resources
Useful
ResourcesVideosMaterials

ABRYSVO®▼(Respiratory Syncytial Virus Vaccine [bivalent, recombinant]) Prescribing Information for the United Kingdom click here.  

ABRYSVO and the UK RSV National Immunisation Programme


ABRYSVO is indicated for1:
  • Passive protection against lower respiratory tract disease (LRTD)caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age following maternal immunisation during pregnancy. For maternal immunisation a dose of 0.5 mL should be administered between weeks 28 and 36 of gestation of pregnancy.
  • Active immunisation for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older
  • Active immunisation for the prevention of lower respiratory tract disease caused by RSV in individuals 18 through 59 years of age who are at increased risk for lower respiratory tract disease caused by RSV.
The use of this vaccine should be in accordance with official recommendations.1

The RSV National Immunisation Programme2

There is an RSV National Immunisation Programme available for maternal immunisation and older adults using ABRYSVO.1,2,3

The use of this vaccine should be in accordance with official recommendations. 

Below are the decisions made by the UKHSA and NHS across the devolved nations on how the RSV programme should be delivered. 
 England
VISIT: GOV.UK Page
Loading Scotland VISIT: Adult NHS Inform Loading VISIT: Pregnancy NHS InformLoading Wales
VISIT: Public Health Wales 
Loading Northern IrelandVISIT: Department of Health NI Loading
VISIT: Green Book Chapter on RSV
Loading

For any further questions or information regarding the programme, speak to your vaccine commisioner. 
Maternal Immunisation with ABRYSVO

Learn more about maternal immunisation with ABRYSVO.

 Learn moreLoading
ABRYSVO in Adults


Find out more about the use of ABRYSVO in adults.

 Learn moreLoading
Preparation of ABRYSVO

 

Watch a video on how to prepare ABRYSVO for administration. Learn moreLoading
Useful Resources

 

Explore the ABRYSVO resources section for useful videos and materials. VideosLoading Materials ABRYSVO (Respiratory Syncytial Virus Vaccine [bivalent, recombinant]) Summary of Product Characteristics for the United Kingdom. Available at: https://www.medicines.org.uk/emc/product/15309.United Kingdom Health Security Agency (UKHSA). Respiratory syncytial virus (RSV) vaccination programme. Available at: https://www.gov.uk/government/collections/respiratory-syncytial-virus-rsv-vaccination-programme. Accessed November 2025.Respiratory Syncytial Virus. The Green Book Chapter 27a. Available at: https://www.gov.uk/government/publications/respiratory-syncytial-virus-the-green-book-chapter-27a. Accessed November 2025
    PP-A1G-GBR-0355. November 2025

    Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search 

    for MHRA Yellow Card in Google Play or Apple App Store

     

    Adverse events should also be reported to Pfizer Medical Information on 01304 616161

    PfizerPro Account

    To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

    Sign In or RegisterAccountSign Out

    This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

     

    This website is brought to you by Pfizer Limited, a company registered in England 

    and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

     

    Copyright © 2025 Pfizer Limited. All rights reserved.

     

    VAT registration number GB201048427

    PP-UNP-GBR-11245. January 2025
    For UK Healthcare Professionals*

    These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

    I confirm that I am a healthcare professional* resident in the United Kingdom.

    If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

    *The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

    PP-UNP-GBR-7812. January 2024.

    YesNo
    You are now leaving PfizerPro​​​​​
    ​
    You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

    Pfizer accepts no responsibility for the content or services of the linked site.

    PP-UNP-GBR-12070. April 2025​​​​​​​
    ​​​​​​​
    You are now leaving PfizerPro

    ​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

    Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer's medicines or business which it has provided or reviewed.

    PP-UNP-GBR-12107. April 2025
    ​​​​​​​